Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.

PloS one - 1 Jan 2013

Pedersen Jannie, Jensen Tanja B, Carlsen Thomas H R, Schønning Kristian, Christensen Peer Brehm, Laursen Alex Lund, Krarup Henrik, Bukh Jens, Weis Nina

Abstract excerpt

The correlation of neutralizing antibodies to treatment outcome in patients with chronic hepatitis C virus (HCV) infection has not been established. The aim of this study was to determine whether neutralizing antibodies could be used as an outcome predictor in patients with chronic HCV, genotype 1, infection treated with pegylated interferon-α and ribavirin. Thirty-nine patients with chronic hepatitis C, genotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Culture Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Recombinant

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Ribavirin

Share to Viral Envelope Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 23667506
DOI: 10.1371/journal.pone.0062674
PMCID: PMC3646876

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.PMID 23667506Read ↗

Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.Semantic proximity Read ↗

Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A InhibitorsSemantic proximity Read ↗

Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.Semantic proximity Read ↗

Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.Semantic proximity Read ↗

Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.Semantic proximity Read ↗

Defining Breadth of Hepatitis C Virus Neutralization.Semantic proximity Read ↗

Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Semantic proximity Read ↗

Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses.Semantic proximity Read ↗

JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in the evaluation of virus neutralization.Semantic proximity Read ↗

Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.Semantic proximity Read ↗

Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.Semantic proximity Read ↗

Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.